Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice

QR Code

Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice

Aim. To evaluate the effect of PCSK9-targeted therapy on lipoprotein(a) (Lp(a)) levels in patients with atherosclerotic cardiovascular diseases who have not achieved the target low-density lipoprotein cholesterol (LDL-C) level (statins at maximum tolerated doses and/or ezetimibe).Material and method...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. I. Sapina, Yu. Yu. Varlamova, M. G. Papyrina, A. S. Bezymyannyy, E. L. Kordzaya, E. Yu. Vasilyeva
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2025-01-01
Series:	Российский кардиологический журнал
Subjects:	lipoprotein(a) atherosclerotic cardiovascular diseases inclisiran
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/6177
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2024-06-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

Observational study of inclisiran effectiveness in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2023-12-01)

New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01)

Is it possible to regress atherosclerotic lesions with long-term treatment with lipoprotein apheresis?
by: Ulrich Julius, et al.
Published: (2024-10-01)

Lipoprotein (a) integrates monocyte-mediated thrombosis and inflammation in atherosclerotic cardiovascular disease
by: Robert S. Rosenson, et al.
Published: (2025-06-01)

The heterogeneity of lipoproteins and their role in the development of cardiovascular diseases
by: E. A. Utkina, et al.
Published: (2019-06-01)

Lipoprotein(a) as underestimated cardiovascular risk factor in Russia. Time to introduce into clinical practice
by: O. I. Afanasyeva, et al.
Published: (2024-10-01)

Elevated levels of lipoprotein(a) and low-density lipoprotein cholesterol in familial hypercholesterolemia patients: is dual primary prevention already in sight?
by: Alpo Vuorio, et al.
Published: (2025-07-01)

Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease in South Asian Individuals
by: Darshan Patel, et al.
Published: (2025-07-01)

The Effects of Inclisiran on the Subclinical Inflammatory Markers of Atherosclerotic Cardiovascular Disease in Patients at High Cardiovascular Risk
by: Mateusz Maligłówka, et al.
Published: (2025-06-01)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023-09-01)

Sex differences in the treatment with PCSK9 monoclonal antibodies- real world experience from a dedicated preventive cardiology clinic
by: Lital Hodeda, et al.
Published: (2025-09-01)

Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues
by: M. V. Zhuravleva, et al.
Published: (2020-09-01)

DETECTION OF MODIFIED LIPOPROTEINS IN ATHEROSCLEROTIC LESIONS OF HUMAN AORTA
by: P. V. Pigarevsky, et al.
Published: (2014-07-01)

Relationship of obesity, low-density lipoprotein cholesterol and myocardial perfusion in patients with risk factors and without atherosclerotic cardiovascular diseases
by: V. B. Sergienko, et al.
Published: (2021-03-01)

Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
by: I. V. Sergienko, et al.
Published: (2023-12-01)

Lipoprotein(a), atherosclerosis and cardiovascular risk
by: E. A. Polyakova, et al.
Published: (2024-12-01)

Atherosclerotic plaque in carotid arteries as a risk marker for cardiovascular events risk in middle aged population
by: A. I. Ershova, et al.
Published: (2018-08-01)

LIPOPROTEIN(A) MEANING AS AN ADDITIONAL MARKER OF CARDIOVASCULAR RISK IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
by: V. A. Korneva, et al.
Published: (2016-06-01)

Atherosclerosis and inflammation – from pathogenesis to treatment: current state of affairs (Part I)
by: A. A. Avagimyan, et al.
Published: (2025-04-01)

The echogenicity of atherosclerotic plaques in the carotid arteries in patients with acute coronary syndrome and its effect on the prognosis of cardiovascular events
by: D. A. Guchaeva, et al.
Published: (2019-06-01)

High Density Lipoproteins: Metabolism, Biological Functions and Risk of cardiovascular pathology
by: N. N. Smirnova, et al.
Published: (2023-12-01)

Clinical burden and management gaps in atherosclerotic cardiovascular disease: A nationwide study of 687,212 patients in Taiwan, 2017–2023
by: Fei-Yuan Hsiao, et al.
Published: (2025-10-01)

Meta-analysis of association between atmospheric ozone exposure and atherosclerotic cardiovascular disease
by: Bingqian WANG, et al.
Published: (2025-06-01)

Subclinical atherosclerosis as a risk factor of cardiovascular events
by: S. A. Boytsov, et al.
Published: (2012-06-01)

METHODS FOR CELLULAR AND MOLECULAR COMPOUND OF ATHEROSCLEROTIC PLAQUES ASSESSMENT: LITERARY REVIEW
by: Yu. V. Saranchina, et al.
Published: (2017-10-01)

First Russian experience of treating dyslipidemia with siRNA drugs in patients after heart transplantation
by: M. A. Simonenko, et al.
Published: (2024-02-01)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023-12-01)

Evaluation of Atherosclerotic Cardiovascular Disease Risk Score in Medical Residents of Imam Hossein Hospital: A Cross-Sectional Study
by: Roxana Sadeghi, et al.
Published: (2025-07-01)

Lipoprotein(a) in the diagnosis of cardiovascular risk. The values of lipoprotein (a) and apolipoprotein B in the adult population of Krasnoyarsk
by: V. S. Emelyanchik, et al.
Published: (2023-08-01)

Evaluating of the accurasy of cardiovascular events predicting using SCORE scale and ultrasound visualization of atherosclerotic plaque in patients of multi-disciplinary hospital in Saint-Petersburg: medium-term monitoring data
by: L. L. Bershtein, et al.
Published: (2019-06-01)

Lipid Profile, PCSK9, ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High‐Grade Prostate Cancer and Men At‐Risk of Prostate Cancer
by: Ann‐Charlotte Bergeron, et al.
Published: (2025-02-01)

Features of the atherosclerotic plaque microbiome in patients after carotid endarterectomy
by: E. P. Kolesova, et al.
Published: (2025-01-01)

BIOCHEMICAL MARKERS OF BONE TISSUE METABOLISM INFLUENCE ON VULNERABILITY OF ATHEROSCLEROTIC LESIONS
by: Ya. N. Polonskaya, et al.
Published: (2016-11-01)

OXIDATIVE-ANTIOXIDANT CHANGES OF LOW-DENSITY LIPOPROTEINS AND THEIR ASSOCIATION WITH ATHEROSCLEROTIC RISK FACTORS IN MALE NOVOSIBIRSK POPULATION
by: Yu. I. Ragino, et al.
Published: (2012-06-01)

Gene Expression and Methylation Levels of PCSK9 Gene in Iraqi Patients with Coronary Artery Disease
by: Marwa M. Al-Attar, et al.
Published: (2023-12-01)

LIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW
by: U. Julius, et al.
Published: (2018-09-01)

Effect modification by life's essential 8 on the association between hearing loss and atherosclerotic cardiovascular disease among US adults
by: Shujie Li, et al.
Published: (2025-09-01)

Association Between Cardiometabolic Index and Mortality Among Patients with Atherosclerotic Cardiovascular Disease: Evidence from NHANES 1999–2018
by: Duo Yang, et al.
Published: (2025-06-01)